From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.

Stefan Stein, Simone Scholz, Joachim Schwäble, Mohammed A. Sadat, Ute Modlich, Stephan Schultze-Strasser, Margarita Diaz, Linping Chen-Wichmann, Uta Müller-Kuller, Christian Brendel, Raffaele Fronza, Kerstin B. Kaufmann, Sonja Naundorf, Nancy K. Pech, Jeffrey Travers, Juan D. Matute, Robert Presson, George Sandusky, Hana Kunkel, Eva RudolfAdelina Dillmann, Christof von Kalle, Klaus Kühlcke, Christopher Baum, Axel Schambach, Mary C. Dinauer, Manfred Schmidt, Manuel Grez

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91(phox)) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.

Original languageEnglish (US)
Pages (from-to)86-98
Number of pages13
JournalHuman gene therapy. Clinical development
Volume24
Issue number2
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Chronic Granulomatous Disease
Genetic Therapy
Hematopoietic System
Phase II Clinical Trials
Clinical Trials, Phase I
Aspergillus fumigatus
Mycoses
Phagocytes
Transgenes
Bacterial Infections
Codon
Superoxides
Safety
Genes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

From bench to bedside : preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. / Stein, Stefan; Scholz, Simone; Schwäble, Joachim; Sadat, Mohammed A.; Modlich, Ute; Schultze-Strasser, Stephan; Diaz, Margarita; Chen-Wichmann, Linping; Müller-Kuller, Uta; Brendel, Christian; Fronza, Raffaele; Kaufmann, Kerstin B.; Naundorf, Sonja; Pech, Nancy K.; Travers, Jeffrey; Matute, Juan D.; Presson, Robert; Sandusky, George; Kunkel, Hana; Rudolf, Eva; Dillmann, Adelina; von Kalle, Christof; Kühlcke, Klaus; Baum, Christopher; Schambach, Axel; Dinauer, Mary C.; Schmidt, Manfred; Grez, Manuel.

In: Human gene therapy. Clinical development, Vol. 24, No. 2, 06.2013, p. 86-98.

Research output: Contribution to journalArticle

Stein, S, Scholz, S, Schwäble, J, Sadat, MA, Modlich, U, Schultze-Strasser, S, Diaz, M, Chen-Wichmann, L, Müller-Kuller, U, Brendel, C, Fronza, R, Kaufmann, KB, Naundorf, S, Pech, NK, Travers, J, Matute, JD, Presson, R, Sandusky, G, Kunkel, H, Rudolf, E, Dillmann, A, von Kalle, C, Kühlcke, K, Baum, C, Schambach, A, Dinauer, MC, Schmidt, M & Grez, M 2013, 'From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.', Human gene therapy. Clinical development, vol. 24, no. 2, pp. 86-98. https://doi.org/10.1089/humc.2013.019
Stein, Stefan ; Scholz, Simone ; Schwäble, Joachim ; Sadat, Mohammed A. ; Modlich, Ute ; Schultze-Strasser, Stephan ; Diaz, Margarita ; Chen-Wichmann, Linping ; Müller-Kuller, Uta ; Brendel, Christian ; Fronza, Raffaele ; Kaufmann, Kerstin B. ; Naundorf, Sonja ; Pech, Nancy K. ; Travers, Jeffrey ; Matute, Juan D. ; Presson, Robert ; Sandusky, George ; Kunkel, Hana ; Rudolf, Eva ; Dillmann, Adelina ; von Kalle, Christof ; Kühlcke, Klaus ; Baum, Christopher ; Schambach, Axel ; Dinauer, Mary C. ; Schmidt, Manfred ; Grez, Manuel. / From bench to bedside : preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. In: Human gene therapy. Clinical development. 2013 ; Vol. 24, No. 2. pp. 86-98.
@article{18dc556466fa4feb91ea95c90c76b580,
title = "From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.",
abstract = "Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91(phox)) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.",
author = "Stefan Stein and Simone Scholz and Joachim Schw{\"a}ble and Sadat, {Mohammed A.} and Ute Modlich and Stephan Schultze-Strasser and Margarita Diaz and Linping Chen-Wichmann and Uta M{\"u}ller-Kuller and Christian Brendel and Raffaele Fronza and Kaufmann, {Kerstin B.} and Sonja Naundorf and Pech, {Nancy K.} and Jeffrey Travers and Matute, {Juan D.} and Robert Presson and George Sandusky and Hana Kunkel and Eva Rudolf and Adelina Dillmann and {von Kalle}, Christof and Klaus K{\"u}hlcke and Christopher Baum and Axel Schambach and Dinauer, {Mary C.} and Manfred Schmidt and Manuel Grez",
year = "2013",
month = "6",
doi = "10.1089/humc.2013.019",
language = "English (US)",
volume = "24",
pages = "86--98",
journal = "Human gene therapy. Clinical development",
issn = "2324-8637",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - From bench to bedside

T2 - preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.

AU - Stein, Stefan

AU - Scholz, Simone

AU - Schwäble, Joachim

AU - Sadat, Mohammed A.

AU - Modlich, Ute

AU - Schultze-Strasser, Stephan

AU - Diaz, Margarita

AU - Chen-Wichmann, Linping

AU - Müller-Kuller, Uta

AU - Brendel, Christian

AU - Fronza, Raffaele

AU - Kaufmann, Kerstin B.

AU - Naundorf, Sonja

AU - Pech, Nancy K.

AU - Travers, Jeffrey

AU - Matute, Juan D.

AU - Presson, Robert

AU - Sandusky, George

AU - Kunkel, Hana

AU - Rudolf, Eva

AU - Dillmann, Adelina

AU - von Kalle, Christof

AU - Kühlcke, Klaus

AU - Baum, Christopher

AU - Schambach, Axel

AU - Dinauer, Mary C.

AU - Schmidt, Manfred

AU - Grez, Manuel

PY - 2013/6

Y1 - 2013/6

N2 - Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91(phox)) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.

AB - Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91(phox)) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.

UR - http://www.scopus.com/inward/record.url?scp=84886691994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886691994&partnerID=8YFLogxK

U2 - 10.1089/humc.2013.019

DO - 10.1089/humc.2013.019

M3 - Article

C2 - 23845071

AN - SCOPUS:84886691994

VL - 24

SP - 86

EP - 98

JO - Human gene therapy. Clinical development

JF - Human gene therapy. Clinical development

SN - 2324-8637

IS - 2

ER -